These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16220555)

  • 1. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation.
    Peccatori J; Barkholt L; Demirer T; Sormani MP; Bruzzi P; Ciceri F; Zambelli A; Da Prada GA; Pedrazzoli P; Siena S; Massenkeil G; Martino R; Lenhoff S; Corradini P; Rosti G; Ringden O; Bregni M; Niederwieser D;
    Cancer; 2005 Nov; 104(10):2099-103. PubMed ID: 16220555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
    Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
    J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.
    Nakayama K; Tannir NM; Liu P; Wathen JK; Cheng YC; Champlin RE; Ueno NT
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):975-85. PubMed ID: 17640602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
    Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
    J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting.
    Bregni M; Bernardi M; Servida P; Pescarollo A; Crocchiolo R; Treppiedi E; Corradini P; Ciceri F; Peccatori J
    Bone Marrow Transplant; 2009 Aug; 44(4):237-42. PubMed ID: 19234510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
    J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
    Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
    Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma.
    Donskov F; von der Maase H
    J Clin Oncol; 2006 May; 24(13):1997-2005. PubMed ID: 16648500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
    Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
    J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
    Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
    Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
    Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
    J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathobiology and prognosis of chromophobe renal cell carcinoma.
    Klatte T; Han KR; Said JW; Böhm M; Allhoff EP; Kabbinavar FF; Belldegrun AS; Pantuck AJ
    Urol Oncol; 2008; 26(6):604-9. PubMed ID: 18367104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.
    Massenkeil G; Roigas J; Nagy M; Wille A; Stroszczynski C; Mapara MY; Loening S; Dörken B; Arnold R
    Bone Marrow Transplant; 2004 Aug; 34(4):309-16. PubMed ID: 15220955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
    Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
    Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic factors in patients with metastatic renal cell carcinoma].
    Inoue R; Takahashi A; Takasugi S; Masumori N; Tsukamoto T; Hasegawa T
    Hinyokika Kiyo; 2010 Feb; 56(2):75-9. PubMed ID: 20185990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma.
    Brookman-Amissah S; Kendel F; Spivak I; Pflanz S; Roigas J; Klotz T; May M
    BJU Int; 2009 May; 103(10):1375-80. PubMed ID: 19040527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.